STOCKHOLM, October 13, 2010 /PRNewswire/ -- Pharmalink AB, a privately held Swedish pharmaceutical company, has received orphan drug designation by the US Food and Drug Administration (FDA) for its product candidate Nefecon (PL-56) for patients with IgA nephropathy, also referred to as Berger's Disease.

READING, England and BEDMINSTER, N.J., Oct.

In the news release, Archimedes Pharma Announces Publication of a Pivotal Clinical Study of Fentanyl Pectin Nasal Spray (FPNS) in Pain, the Peer-Reviewed Journal from the International Association for the Study of Pain, issued 04-Oct-2010 by Archimedes Pharma over PR Newswire, we are advised by the company that the second paragraph, last sentence, the link should read "http://www.ncbi.nlm.nih.gov/pubmed/20800358" rather than "http://www.jpain.org/" as originally issued inadvertently.

READING, England and BEDMINSTER, N.J., Aug.

READING, England, June 25, 2010 /PRNewswire/ -- Archimedes Pharma ("Archimedes"), a leading specialty pharma company, today announced that its lead product, PecFent*, has received a Positive Opinion from the Committee for Human Medicinal Products (CHMP), of the European Medicines Agency (EMA). The CHMP is recommending PecFent, an innovative fentanyl nasal spray, be authorised for marketing in European Union countries for the treatment of breakthrough cancer pain (BTCP) - sudden, unpredictable episodes of intense pain that occur despite background pain medication. Jeffrey H.